23
Views
39
CrossRef citations to date
0
Altmetric
Cell Growth and Development

The Protein Kinase Snf1 Is Required for Tolerance to the Ribonucleotide Reductase Inhibitor Hydroxyurea

, &
Pages 2560-2572 | Received 20 Aug 2003, Accepted 22 Dec 2003, Published online: 27 Mar 2023
 

Abstract

The Snf1/AMP-activated kinases are involved in a wide range of stress responses in eukaryotic cells. We discovered a novel role for the Snf1 kinase in the cellular response to genotoxic stress in yeast. snf1 mutants are hypersensitive to hydroxyurea (HU), methyl-methane sulfonate, and cadmium, but they are not sensitive to several other genotoxic agents. HU inhibits ribonucleotide reductase (RNR), and deletion of SNF1 also increased the growth defects of an rnr4 ribonucleotide reductase mutant. The snf1 mutant has a functional checkpoint response to HU insofar as cells arrest division normally and derepress the transcription of RNR genes. The sensitivity of snf1 to HU or to RNR4 deletion may be due to posttranscriptional defects in RNR function or to defects in the repair of, and recovery from, stalled replication forks. The Mig3 repressor was identified as one target of Snf1 in this pathway. Genetic and biochemical analyses suggest that a weak kinase activity is sufficient to confer resistance to HU, whereas a high level of kinase activity is required for optimal growth on carbon sources other than glucose. Quantitative regulation of Snf1 kinase activity may contribute to the specificity of the effector responses that it controls.

We thank Marian Carlson for providing a large number of yeast strains and plasmids; Martin Schmidt for the generous gift of anti-Snf1-phospho-Thr-210 antibodies and plasmids; Shelley Berger, Stéphane Marcand, and Aaron Straight for plasmids; and Marie-Claude Marsolier, Cyril Buhler, and Lea Jessup for a critical review of the manuscript.

C.D. was supported by an Allocation Couplée de l'Ecole Normale Supérieure de Paris. This work was also supported by grants from the Association pour la Recherche sur le Cancer (ARC grant number 4470) and Electricité de France.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.